DUBLIN--(BUSINESS WIRE)--The "Competitor Analysis: CD40, GITR, OX40, 4-1BB, CD27, ICOS & Other Immune Checkpoint Activators 2018" report has been added to ResearchAndMarkets.com's offering. This ...

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Competitor Analysis: Activators of Immune Checkpoints CD40, GITR, OX40, 4-1BB, CD27 & ICOS" report to their offering.

Fc改変によりFcγRIIBへの結合性を高めたCD40アゴニスト抗体2141-V11の膀胱内投与は、BCG不応性の筋層非浸潤性膀胱癌（NMIBC）において極めて安全性が高く、38%の患者で完全奏効（CR）が得られるなど、有望な抗腫瘍活性を示すことがフェーズ1試験で示された。

Researchers at University of Pennsylvania are investigating anti-CD40 antibodies in a number of combinations in pancreatic cancer and other malignancies in which the baseline line immune response ...

As lead candidate mipletamig continues to outperform efficacy and safety benchmarks in AML trials, APVO711 exemplifies emerging innovation from Aptevo's proprietary ADAPTIR® platform In ...

Apexigen has begun collaborating with Yale Cancer Center on an early-stage clinical trial that combines the biotech’s APX005M CD40 activator with Bristol-Myers Squibb’s Opdivo and cabiralizumab, an ...

"With APVO711, we're advancing an innovative dual-mechanism approach to immunotherapy-one that not only boosts the immune system through PD-L1 blockade but also facilitates T-cell priming via CD40 ...

SEATTLE, WASHINGTON / ACCESS Newswire / May 8, 2025 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on ...

The CD40 molecule transmits a signal that abrogates apoptosis induced by ligation of the antigen receptor (BCR) in both primary B cells and B-cell lines such as WEHI-231. Expression of Bcl-xL and A1, ...